Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance.

O'Neill PM, Amewu RK, Charman SA, Sabbani S, Gnädig NF, Straimer J, Fidock DA, Shore ER, Roberts NL, Wong MH, Hong WD, Pidathala C, Riley C, Murphy B, Aljayyoussi G, Gamo FJ, Sanz L, Rodrigues J, Cortes CG, Herreros E, Angulo-Barturén I, Jiménez-Díaz MB, Bazaga SF, Martínez-Martínez MS, Campo B, Sharma R, Ryan E, Shackleford DM, Campbell S, Smith DA, Wirjanata G, Noviyanti R, Price RN, Marfurt J, Palmer MJ, Copple IM, Mercer AE, Ruecker A, Delves MJ, Sinden RE, Siegl P, Davies J, Rochford R, Kocken CHM, Zeeman AM, Nixon GL, Biagini GA, Ward SA.

Nat Commun. 2017 May 24;8:15159. doi: 10.1038/ncomms15159.

2.

Plasmodium falciparum K13 Mutations Differentially Impact Ozonide Susceptibility and Parasite Fitness In Vitro.

Straimer J, Gnädig NF, Stokes BH, Ehrenberger M, Crane AA, Fidock DA.

MBio. 2017 Apr 11;8(2). pii: e00172-17. doi: 10.1128/mBio.00172-17.

3.

Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling.

Le Bihan A, de Kanter R, Angulo-Barturen I, Binkert C, Boss C, Brun R, Brunner R, Buchmann S, Burrows J, Dechering KJ, Delves M, Ewerling S, Ferrer S, Fischli C, Gamo-Benito FJ, Gnädig NF, Heidmann B, Jiménez-Díaz MB, Leroy D, Martínez MS, Meyer S, Moehrle JJ, Ng CL, Noviyanti R, Ruecker A, Sanz LM, Sauerwein RW, Scheurer C, Schleiferboeck S, Sinden R, Snyder C, Straimer J, Wirjanata G, Marfurt J, Price RN, Weller T, Fischli W, Fidock DA, Clozel M, Wittlin S.

PLoS Med. 2016 Oct 4;13(10):e1002138. doi: 10.1371/journal.pmed.1002138. eCollection 2016 Oct.

4.

Limited polymorphisms in k13 gene in Plasmodium falciparum isolates from Dakar, Senegal in 2012-2013.

Torrentino-Madamet M, Fall B, Benoit N, Camara C, Amalvict R, Fall M, Dionne P, Ba Fall K, Nakoulima A, Diatta B, Diemé Y, Ménard D, Wade B, Pradines B.

Malar J. 2014 Dec 4;13:472. doi: 10.1186/1475-2875-13-472.

5.

Examining Plasmodium falciparum and P. vivax clearance subsequent to antimalarial drug treatment in the Myanmar-China border area based on quantitative real-time polymerase chain reaction.

Lo E, Nguyen J, Oo W, Hemming-Schroeder E, Zhou G, Yang Z, Cui L, Yan G.

BMC Infect Dis. 2016 Apr 16;16:154. doi: 10.1186/s12879-016-1482-6.

6.

Artemisinin Action and Resistance in Plasmodium falciparum.

Tilley L, Straimer J, Gnädig NF, Ralph SA, Fidock DA.

Trends Parasitol. 2016 Sep;32(9):682-696. doi: 10.1016/j.pt.2016.05.010. Epub 2016 Jun 9. Review.

7.

Gametocytes from K13 Propeller Mutant Plasmodium falciparum Clinical Isolates Demonstrate Reduced Susceptibility to Dihydroartemisinin in the Male Gamete Exflagellation Inhibition Assay.

Lozano S, Gamallo P, González-Cortés C, Presa Matilla JL, Fairhurst RM, Herreros E, Amaratunga C, Rodrigues J.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e01426-18. doi: 10.1128/AAC.01426-18. Print 2018 Dec.

8.

A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria.

Mbengue A, Bhattacharjee S, Pandharkar T, Liu H, Estiu G, Stahelin RV, Rizk SS, Njimoh DL, Ryan Y, Chotivanich K, Nguon C, Ghorbal M, Lopez-Rubio JJ, Pfrender M, Emrich S, Mohandas N, Dondorp AM, Wiest O, Haldar K.

Nature. 2015 Apr 30;520(7549):683-7. doi: 10.1038/nature14412. Epub 2015 Apr 15.

9.

Artemisinin resistance phenotypes and K13 inheritance in a Plasmodium falciparum cross and Aotus model.

Sá JM, Kaslow SR, Krause MA, Melendez-Muniz VA, Salzman RE, Kite WA, Zhang M, Moraes Barros RR, Mu J, Han PK, Mershon JP, Figan CE, Caleon RL, Rahman RS, Gibson TJ, Amaratunga C, Nishiguchi EP, Breglio KF, Engels TM, Velmurugan S, Ricklefs S, Straimer J, Gnädig NF, Deng B, Liu A, Diouf A, Miura K, Tullo GS, Eastman RT, Chakravarty S, James ER, Udenze K, Li S, Sturdevant DE, Gwadz RW, Porcella SF, Long CA, Fidock DA, Thomas ML, Fay MP, Sim BKL, Hoffman SL, Adams JH, Fairhurst RM, Su XZ, Wellems TE.

Proc Natl Acad Sci U S A. 2018 Dec 4;115(49):12513-12518. doi: 10.1073/pnas.1813386115. Epub 2018 Nov 19.

10.

Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast Asia.

Takala-Harrison S, Jacob CG, Arze C, Cummings MP, Silva JC, Dondorp AM, Fukuda MM, Hien TT, Mayxay M, Noedl H, Nosten F, Kyaw MP, Nhien NT, Imwong M, Bethell D, Se Y, Lon C, Tyner SD, Saunders DL, Ariey F, Mercereau-Puijalon O, Menard D, Newton PN, Khanthavong M, Hongvanthong B, Starzengruber P, Fuehrer HP, Swoboda P, Khan WA, Phyo AP, Nyunt MM, Nyunt MH, Brown TS, Adams M, Pepin CS, Bailey J, Tan JC, Ferdig MT, Clark TG, Miotto O, MacInnis B, Kwiatkowski DP, White NJ, Ringwald P, Plowe CV.

J Infect Dis. 2015 Mar 1;211(5):670-9. doi: 10.1093/infdis/jiu491. Epub 2014 Sep 1.

11.

Independent Emergence of the Plasmodium falciparum Kelch Propeller Domain Mutant Allele C580Y in Guyana.

Chenet SM, Akinyi Okoth S, Huber CS, Chandrabose J, Lucchi NW, Talundzic E, Krishnalall K, Ceron N, Musset L, Macedo de Oliveira A, Venkatesan M, Rahman R, Barnwell JW, Udhayakumar V.

J Infect Dis. 2016 May 1;213(9):1472-5. doi: 10.1093/infdis/jiv752. Epub 2015 Dec 21.

PMID:
26690347
12.

Updates on k13 mutant alleles for artemisinin resistance in Plasmodium falciparum.

Zaw MT, Emran NA, Lin Z.

J Microbiol Immunol Infect. 2018 Apr;51(2):159-165. doi: 10.1016/j.jmii.2017.06.009. Epub 2017 Jun 29. Review.

13.

Introduction of F446I mutation in the K13 propeller gene leads to increased ring survival rates in Plasmodium falciparum isolates.

Wang J, Huang Y, Zhao Y, Ye R, Zhang D, Pan W.

Malar J. 2018 Jul 5;17(1):248. doi: 10.1186/s12936-018-2396-0.

14.

Plasmodium vivax and Plasmodium falciparum ex vivo susceptibility to anti-malarials and gene characterization in Rondônia, West Amazon, Brazil.

Aguiar AC, Pereira DB, Amaral NS, De Marco L, Krettli AU.

Malar J. 2014 Feb 28;13:73. doi: 10.1186/1475-2875-13-73.

15.

A Variant PfCRT Isoform Can Contribute to Plasmodium falciparum Resistance to the First-Line Partner Drug Piperaquine.

Dhingra SK, Redhi D, Combrinck JM, Yeo T, Okombo J, Henrich PP, Cowell AN, Gupta P, Stegman ML, Hoke JM, Cooper RA, Winzeler E, Mok S, Egan TJ, Fidock DA.

MBio. 2017 May 9;8(3). pii: e00303-17. doi: 10.1128/mBio.00303-17.

16.

Identification of a 1,2,4,5-tetraoxane antimalarial drug-development candidate (RKA 182) with superior properties to the semisynthetic artemisinins.

O'Neill PM, Amewu RK, Nixon GL, Bousejra ElGarah F, Mungthin M, Chadwick J, Shone AE, Vivas L, Lander H, Barton V, Muangnoicharoen S, Bray PG, Davies J, Park BK, Wittlin S, Brun R, Preschel M, Zhang K, Ward SA.

Angew Chem Int Ed Engl. 2010 Aug 2;49(33):5693-7. doi: 10.1002/anie.201001026. No abstract available.

PMID:
20629058
17.

Understanding artemisinin-resistant malaria: what a difference a year makes.

Fairhurst RM.

Curr Opin Infect Dis. 2015 Oct;28(5):417-25. doi: 10.1097/QCO.0000000000000199. Review.

18.

Insight into k13-propeller gene polymorphism and ex vivo DHA-response profiles from Cameroonian isolates.

Menard S, Tchoufack JN, Maffo CN, Nsango SE, Iriart X, Abate L, Tsapi MT, Awono-Ambéné PH, Abega Mekongo FA, Morlais I, Berry A.

Malar J. 2016 Nov 26;15(1):572.

19.

Absence of association between polymorphisms in the K13 gene and the presence of Plasmodium falciparum parasites at day 3 after treatment with artemisinin derivatives in Senegal.

Madamet M, Kounta MB, Wade KA, Lo G, Diawara S, Fall M, Bercion R, Nakoulima A, Fall KB, Benoit N, Gueye MW, Fall B, Diatta B, Pradines B.

Int J Antimicrob Agents. 2017 Jun;49(6):754-756. doi: 10.1016/j.ijantimicag.2017.01.032. Epub 2017 Apr 24.

PMID:
28450175
20.

An endoperoxide-based hybrid approach to deliver falcipain inhibitors inside malaria parasites.

Oliveira R, Newton AS, Guedes RC, Miranda D, Amewu RK, Srivastava A, Gut J, Rosenthal PJ, O'Neill PM, Ward SA, Lopes F, Moreira R.

ChemMedChem. 2013 Sep;8(9):1528-36. doi: 10.1002/cmdc.201300202. Epub 2013 Jul 12.

PMID:
23853126

Supplemental Content

Support Center